Medical Director
CurrentClinical and scientific development of multiple assets focused on rare kidney disease, initially IgA nephropathy, but also FSGS, Alport Syndrome, DKD. Responsible for clinical trial site engagement for our Phase 1-3 programs in the US, Canada & EU.